T Cell Receptor Alpha-Joining 9: A Potential Drug Target for Cancer

Target Name: TRAJ9

NCBI ID: G28746

TRAJ9

Other Name(s): T cell receptor alpha joining 9

T Cell Receptor Alpha-Joining 9: A Potential Drug Target for Cancer

Traj9, also known as T cell receptor alpha-joining 9, is a protein that is expressed in T cells, a type of white blood cell that plays a crucial role in the immune system. T cells are responsible for detecting and responding to foreign substances in the body, and their activation and function are closely regulated by the T cell receptor alpha-joining 9 protein.

The T cell receptor alpha-joining 9 protein is a transmembrane protein that is composed of two extracellular domains and an intracellular domain. The extracellular domains of the protein include an N-terminus that is involved in cell signaling and a C-terminus that is involved in protein-protein interactions. The intracellular domain of the protein includes a tyrosine kinase domain that is responsible for the protein's signaling functions.

T cell receptor alpha-joining 9 is involved in the regulation of T cell activation and proliferation. When T cells are activated, the protein is activated and begins to translocate to the plasma membrane. There, it interacts with the T cell receptor alpha-joining 1 protein, which is also a component of the T cell receptor complex. This interaction between the two proteins allows for the formation of a complex that is involved in the regulation of T cell signaling.

In addition to its role in T cell signaling, T cell receptor alpha-joining 9 is also involved in the regulation of cancer cell growth and survival. It has been shown to play a role in the regulation of cancer cell stem cell properties, and has been identified as a potential drug target for the treatment of various types of cancer.

The potential drug targets for T cell receptor alpha-joining 9 include inhibitors of the protein's signaling functions, as well as inhibitors of its interactions with other proteins. One approach to targeting this protein is to use small molecules that are known to inhibit the activity of the protein's tyrosine kinase domain. These small molecules can be administered to T cells, and their effects on T cell receptor alpha-joining 9 signaling can be measured.

Another approach to targeting T cell receptor alpha-joining 9 is to use antibodies that are specifically designed to block the protein's interaction with other proteins. These antibodies can be used to target the protein directly, and their effects on T cell receptor alpha-joining 9 signaling can also be measured.

In conclusion, T cell receptor alpha-joining 9 is a protein that is involved in the regulation of T cell signaling and has been identified as a potential drug target for the treatment of various types of cancer. The use of small molecules and antibodies to inhibit the protein's signaling functions and interactions with other proteins is a promising approach to targeting this protein and may lead to new treatments for cancer.

Protein Name: T Cell Receptor Alpha Joining 9

The "TRAJ9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets